CN Patent

CN114057651B — 含酰胺基的tyk2抑制剂化合物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2025-05-27 · 1y expired

What this patent protects

本申请属于药物化学领域，提供了一种含酰胺基的TYK2抑制剂化合物，具体而言涉式I化合物及其制备方法，并涉及其在制备治疗或预防TYK2相关疾病的药物中的用途。

USPTO Abstract

本申请属于药物化学领域，提供了一种含酰胺基的TYK2抑制剂化合物，具体而言涉式I化合物及其制备方法，并涉及其在制备治疗或预防TYK2相关疾病的药物中的用途。

Drugs covered by this patent

Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN114057651B
Jurisdiction: CN
Classification: —
Expires: 2025-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.